~~<i id='77F4947ED3'><strike id='77F4947ED3'><tt id='77F4947ED3'><pre id='77F4947ED3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

focus

author：leisure time 2025-10-03 01:04:23 - browse：2

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： 'Screen and refer' systems are hurting patients

focus

explore

entertainment

explore

focus

ForensicmedicalexaminersworkatthescenewhereanunidentifiedmanwaskilledinApatzingan,Mexico,Sunday,July

WSS

Beware reading your test results before your doctor does

Undocumented workers face uncertainty as immigration law takes effect in Florida

Fed up with FDA, ALS advocates consider a take

FDA weighs limits of animal data in assessing artificial wombs

Lupron, used to halt puberty in children, may cause lasting health problems

Fed up with FDA, ALS advocates consider a take

Wikipedia

focus

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

People with substance use disorder deserve online privacy

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Information blocking fines are now fair game in health care

New air purifier tech could be key to improving indoor air quality

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

23andMe had bad news about my health. I wish a person had delivered it

A letter from the executive editor: The 2023 STATUS List

Drug repurposing or repositioning? The language matters

How the messy conversation about Dolly changed bioethics

focus

Information blocking fines are now fair game in health care

'A game

Fatty liver disease was alleviated by Lilly’s ‘triple

FDA weighs limits of animal data in assessing artificial wombs

Canadians with cystic fibrosis outlive Americans by a decade

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

explore

entertainment

explore

focus